Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Systematic reviews and cancer research: a suggested stepwise approach

(2018) George A. Kelley et al.   BMC CANCER

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

(2018) David Waterhouse et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management

(2018) Christophoros Astaras et al.   Current Neurology and Neuroscience Reports

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

(2018) Marina Chiara Garassino et al.   LANCET ONCOLOGY

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer

(2018) Wei You et al.   Journal of Cancer

Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios

(2018) Rebecca Tay et al.   Journal of Thoracic Disease

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy

(2018) C E Higham et al.   Endocrine Connections

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

(2018) Heinz Läubli et al.   Journal for ImmunoTherapy of Cancer

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048

(2018) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

(2017) D. Makarious et al.   EUROPEAN JOURNAL OF CANCER

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

(2017) Solange Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

(2017) Clélia Coutzac et al.   Journal of Crohns & Colitis

Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab

(2017) Daniel R. Matson et al.   JOURNAL OF FORENSIC SCIENCES

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report

(2017) Hong Li et al.   Journal of Hematology & Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

(2017) James L Gulley et al.   LANCET ONCOLOGY

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma

(2017) Yu-Hsiu Chen et al.   MEDICINE

Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer

(2017) Xiaoying Sun et al.   MEDICINE

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

(2017) Riccardo Mezzadra et al.   NATURE

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

(2017) Guillermo De Velasco et al.   Cancer Immunology Research

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

(2017) Peng-Fei Wang et al.   Frontiers in Pharmacology

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

(2017) James Luke Godwin et al.   Journal for ImmunoTherapy of Cancer

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade

(2017) Heinz Läubli et al.   Journal for ImmunoTherapy of Cancer

Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes

(2016) Sung Hye Kong et al.   ACTA DIABETOLOGICA

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

(2016) Anushree C. Shirali et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion

(2016) Igal Kushnir et al.   CARDIOLOGY

Pericardial effusion with tamponade physiology induced by nivolumab

(2016) Jennifer Nesfeder et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy

(2016) Kurt B. Schaberg et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)

(2016) Puey Ling Chia et al.   JOURNAL OF IMMUNOTHERAPY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma

(2016) V. Gounant et al.   LUNG CANCER

Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab

(2016) Samer Tabchi et al.   LUNG CANCER

Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report

(2016) Kazuhiko Ikeuchi et al.   LUNG CANCER

Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung

(2016) H. Semper et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer

(2016) M. Nishino et al.   Cancer Immunology Research

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

(2016) J. Naidoo et al.   Cancer Immunology Research

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies

(2015) Steven Orlov et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

A basic introduction to fixed-effect and random-effects models for meta-analysis

(2010) Michael Borenstein et al.   Research Synthesis Methods